Hormone Resistant Prostate Cancer Completed Phase 0 Trials for Bicalutamide (DB01128)

Also known as: Hormone-Resistant Prostate Cancer

IndicationStatusPhase
DBCOND0038482 (Hormone Resistant Prostate Cancer)Completed0
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01050842Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate CancerTreatment